A Novel Fluorescent Ductal Needle for Localization and Sampling of Micro Lesions in Breast Ducts
Recruiting
N/A
Interventional Study
Mammary Tumor
Nipple Discharge
Breast Ductal Carcinoma In Situ
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 75
- Sex
- Female
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 300 (estimated)
- Sponsor
- The Fourth Affiliated Hospital of China Medical University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This prospective, multicenter cohort study investigates the differences in the reliability of rapid pathology compared to postoperative pathology when utilizing a novel fluorescent localization needle equipped with a controllable shedding quantum dot chiral nanofluorescent coating, in contrast to traditional localization techniques for breast duct lesions. The principal objective is to assess the …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Female patients aged 18-75 years.
2. Patients scheduled to undergo duct excision surgery.
3. Patients who are capable of providing written informed consent and adhering to the study protocols.
Exclusion Criteria:
1. Pregnant or breastfeeding.
2. Patients who have known alle…
Contacts